Researchers Studying IV Medicine to Treat Pediatric Adamantinomatous Craniopharyngioma (ACP)
Phase: Recruiting
First Posted: January
Condition(s): Adamantinomatous Craniopharyngioma (ACP)
NCT Number: NCT05233397 Other Study ID Number(s): CONNECT1905
What Is the Purpose of This Study?
To study an IV infusion drug to see if it is effective in treating ACP patients who may or may not have undergone surgery or radiation as it may help shrink this type of brain tumor or slow its growth.
Who Can Take Part in This Study?
People who may be eligible for this study:
- Have histologically confirmed progressive or recurrent adamantinomatous craniopharyngioma (ACP).
- Are 1-25 years old.
For a full list of eligibility requirements, visit https://clinicaltrials.gov/study/NCT05233397
What Will Happen During This Study?
- Patients will have an IV infusion every 2 weeks.
- Therapy may continue for up to two years (26 cycles).
Principal Investigator
Discover More Research
Explore additional studies relating to neuro-oncologyYour Might Also Be Interested In
Neuro-Oncology
Our highly experienced and internationally recognized team of pediatric neuro-oncologists, neurosurgeons and neuroradiologists will care for your child by providing the most advanced and innovative treatments, while at the same time, paying careful attention to all the needs and concerns of your child and family.
Craniopharyngioma
Craniopharyngioma is a rare tumor that develops at the central, bottom portion of the brain. It can affect the pituitary gland, optic pathway, and hypothalamus.
Brain Tumors
Brain tumors are the most common solid tumors in children. Primary brain tumors start in the brain and usually do not spread outside the brain tissue.